This inventor holds 4 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignees: Famewave Ltd., Syntimmune, Inc.. Active years: 2020-2024.
Company Filing History:
Years Active: 2020-2024
Title: Robert George E Holgate: Innovator in Humanized Antibodies
Introduction
Robert George E Holgate is a notable inventor based in Royston, GB. He has made significant contributions to the field of biotechnology, particularly in the development of humanized antibodies. With a total of 4 patents to his name, Holgate's work has the potential to impact cancer treatment and diagnostics.
Latest Patents
Holgate's latest patents include innovative humanized antibodies against CEACAM1. These antibodies are capable of specific binding to human CEACAM1 molecules that contain human-to-murine back-mutations in non-CDR variable regions. The patents also provide their encoding polynucleotide sequences. Additionally, pharmaceutical compositions comprising these antibodies, along with methods for their use in treating and diagnosing cancer and other conditions, are included in his work.
Career Highlights
Throughout his career, Holgate has worked with various companies, including Famewave Ltd. and Syntimmune, Inc. His expertise in biotechnology and antibody development has positioned him as a key figure in his field.
Collaborations
Holgate has collaborated with notable professionals, including Tehila Ben-Moshe and Yair Sapir. These collaborations have further enhanced his research and development efforts in the biotechnology sector.
Conclusion
Robert George E Holgate is a distinguished inventor whose work in humanized antibodies is paving the way for advancements in cancer treatment. His contributions to biotechnology are invaluable and continue to influence the industry.